MCRB: Seres Therapeutics Company Short-Term Debt

Symbol and logo of brand Seres Therapeutics (MCRB)

Seres Therapeutics (MCRB) is developing microbiome-based medicines in partnership with Nestle Health Science for the therapy of intestinal inflammation. The business relies on the creation of anti-infective agents, yet financial stability remains under threat. Critical factors include the sales volume of core drugs and the level of R&D expenditures, which stands at 0.01. Serving as the primary valuation tool, this price chart clearly demonstrates the company's current market dynamics.

MCRB (Seres Therapeutics Inc.) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Metric breakdowns and analytics for Seres Therapeutics, Inc (MCRB)

- current quotes and average value forecast:
Price Chart Seres Therapeutics, Inc.|MCRB - Fair Value Consensus
- market capitalization information:
Market Value Seres Therapeutics, Inc.|MCRB - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Seres Therapeutics|MCRB - Book Capitalization|Market Cap to Net Assets Ratio serestherapeutics.com|MCRB - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Seres Therapeutics|MCRB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Seres Therapeutics|MCRB - Company Aggregate Debt|Debts to Book Capitalization Seres Therapeutics, Inc.|MCRB - Long-Term Liabilities|Company Short-Term Debts Seres Therapeutics|Quick Ratio serestherapeutics.com
- net income and valuation multiples indicators:
MCRB - Net Income
Fundamental valuation:Seres Therapeutics, Inc. (MCRB)
Manufactured products of Seres Therapeutics

This indicator aggregates all Seres Therapeutics (MCRB) liabilities with a maturity of up to one year. The metric measures current liquidity and the cost of servicing borrowed capital in real-time. For the biotechnology sector, characterized by capital-intensive microbiome research, controlling this burden is critical. Stringent FDA oversight extends payback periods, increasing reliance on loans. The dynamics of the company's short-term borrowings allow for an assessment of the business's resilience to default.

Key competitors

SMMT - Company Short-Term Debt|Company Short-Term Loans and Borrowings MRNA (Moderna Inc)|Vaxcyte Corp (PCVX) - Company Short-Term Debt|Company Current Liabilities Tarsus Corp|CRMD (CorMedix Inc.) - Company Short-Term Debts|Company Short-Term Debts sperotherapeutics.com|Company Current Liabilities SCYX (SCYNEXIS, Inc.)|ANTX (an2therapeutics.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts PYPD (PolyPid)|Short-Term Debt Volume YS Biopharma Co., Ltd. (LSB)|ITRM - Company Short-Term Debt|PHGE (BiomX Inc.) - Company Short-Term Indebtedness|SNGX: Company Short-Term Debts|Current Liabilities SXTP (60 Degrees Pharmaceuticals, Inc.)|OGEN (Oragenics, Inc.) - Company Short-Term Debts|Short-Term Debt Onconetix Corporation ONCO|Company Short-Term Debts OPGN